KPTI News and Press, Karyopharm Therapeutics Inc. From 12/05/22

Karyopharm Announces $165 Million Private Placement PR Newswire NEWTON, Mass. , Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ente...

Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis PR Newswire – Key Opinion Leaders to Review Highlights from Updated Phase 1 Data to be Presented at ASH 2022 at Company Sponsored Event on ...

RBC Capital Markets has upgraded Karyopharm Therapeutics ( NASDAQ: KPTI ) to outperform from market perform saying the company's opportunities are discounted in the stock price. The firm also upped its price target to $10 from $7 (~120% upside based on Thursday's close). ...

Karyopharm Therapeutics ( NASDAQ: KPTI ) stock rose ~9% premarket Friday after Q3 results beat estimates and the company maintained its FY22 outlook. Net loss narrowed to -$36.32M, compared to -$51.81M in Q3 2021. Total revenue declined -4% Y/Y to $36.14M. ...

Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q3 2022 Earnings Call Nov 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q3 2022 Earnings Call Transcript

Karyopharm Therapeutics Inc. (KPTI) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Elhan Webb - Senior Vice President-Investor Relations Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Chief Commercia...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Karyopharm Therapeutics Inc. 2022 Q3 - Results - Earnings Call Presentation

Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q3 GAAP EPS of -$0.45 beats by $0.10 . Revenue of $36.1M (-4.2% Y/Y) beats by $1.27M . Cash, cash equivalents, restricted cash and investments as of September 30, 2022, totaled $150.1 million, compared to ...

Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved Third Quarter 2022 Total Revenue of $36.1 Million , Including XPOVIO® (selinexor) Net Product Revenue of $32.0 Million , a 20 %...

Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022 PR Newswire – Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activ...